{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:35:33Z","timestamp":1778610933437,"version":"3.51.4"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Lung transplantation is an important treatment option for various end-stage lung diseases. However, survival remains limited due to graft rejection and infections. Despite that fungal infections are frequent and carry a bad prognosis, there is currently no consensus on efficacy, optimal drug, route, or duration of antifungal prophylaxis. This narrative review summarizes current strategies for antifungal prophylaxis after lung transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>English language articles in Embase, Pubmed, UptoDate, and bibliographies were used to assess the efficacy and safety of available antifungal agents for prophylaxis in adult lung transplant recipients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Overall, there are limited high-quality data. Universal prophylaxis is more widely used and may be preferable over targeted prophylaxis. Both formulations of inhaled amphotericin B and systemic azoles are effective at reducing fungal infection rates, yet with their own specific advantages and disadvantages. The benefit of combination regimens has yet to be proven. Considering the post-transplant timing of the onset of fungal infections, postoperative prophylaxis during the first postoperative months seems indicated for most patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Based on existing literature, universal antifungal prophylaxis with inhaled amphotericin B and systemic voriconazole for at least 3\u20136 mo after lung transplantation may be advisable, with a slight preference for amphotericin B because of its better safety profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003717","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T09:30:38Z","timestamp":1614763838000},"page":"2538-2545","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Antifungal Prophylaxis After Lung Transplantation: Where Are We Now?"],"prefix":"10.1097","volume":"105","author":[{"given":"Wim","family":"De Mol","sequence":"first","affiliation":[{"name":"Faculty of Medicine, KU Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Bos","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Beeckmans","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, KU Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium."},{"name":"Department of Laboratory Medicine and National Reference Center for Mycosis, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium."},{"name":"Department Pharmacy, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert M.","family":"Verleden","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium."},{"name":"Department CHROMETA, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Vos","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium."},{"name":"Department CHROMETA, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match.","volume":"38","author":"Chambers","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/QCO.0b013e3283630e67","article-title":"Is universal antifungal prophylaxis mandatory in lung transplant patients?","volume":"26","author":"Schaenman","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0037-1617443","article-title":"Fungal infections complicating lung transplantation.","volume":"39","author":"Clark","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ccm.2017.04.011","article-title":"Fungal infections after lung transplantation.","volume":"38","author":"Kennedy","year":"2017","journal-title":"Clin Chest Med"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/TP.0000000000001050","article-title":"Antifungal prophylaxis in lung transplant recipients.","volume":"100","author":"Patel","year":"2016","journal-title":"Transplantation"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"e13437","DOI":"10.1111\/ctr.13437","article-title":"Echinocandin use in lung transplant recipients.","volume":"32","author":"Al Jishi","year":"2018","journal-title":"Clin Transplant"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijantimicag.2014.05.013","article-title":"Antifungal prophylaxis in lung transplantation.","volume":"44","author":"Neoh","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/cid\/ciz156","article-title":"Invasive fungal infection after lung transplantation: epidemiology in the setting of antifungal prophylaxis.","volume":"70","author":"Baker","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"414","DOI":"10.21037\/atm.2020.03.102","article-title":"Infection prophylaxis and management of fungal infections in lung transplant.","volume":"8","author":"Villalobos","year":"2020","journal-title":"Ann Transl Med"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.resinv.2015.08.005","article-title":"Invasive pulmonary aspergillosis in organ transplants","volume":"54","author":"Geltner","year":"2016","journal-title":"Respir Investig"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/ctr.12854","article-title":"Is universal antifungal prophylaxis mandatory in adults after lung transplantation? A review and meta-analysis of observational studies.","volume":"30","author":"Pilarczyk","year":"2016","journal-title":"Clin Transplant"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transplant"},{"key":"R14-20250607","first-page":"ciaa652","article-title":"Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients. [published online ahead of print August 28, 2020].","author":"Samanta","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/tri.12679","article-title":"10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation.","volume":"29","author":"Peghin","year":"2016","journal-title":"Transpl Int"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"e13448","DOI":"10.1111\/tid.13448","article-title":"Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation.","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Husain","year":"2019","journal-title":"Clin Transplant"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/TP.0b013e318255f864","article-title":"A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis.","volume":"94","author":"Koo","year":"2012","journal-title":"Transplantation"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/tid.12071","article-title":"Preemptive treatment with voriconazole in lung transplant recipients.","volume":"15","author":"Neoh","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"e13333","DOI":"10.1111\/tid.13333","article-title":"Antifungal prophylaxis in lung transplant recipients: a systematic review and meta-analysis.","volume":"22","author":"Pennington","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/tid.12337","article-title":"Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national survey.","volume":"17","author":"He","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"e13630","DOI":"10.1111\/ctr.13630","article-title":"Antifungal prophylaxis in lung transplant: a survey of United States\u2019 transplant centers.","volume":"33","author":"Pennington","year":"2019","journal-title":"Clin Transplant"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1345\/aph.1M377","article-title":"Prophylactic antifungal agents used after lung transplantation.","volume":"44","author":"Marino","year":"2010","journal-title":"Ann Pharmacother"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.healun.2016.01.007","article-title":"The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary.","volume":"35","author":"Husain","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1097\/TP.0000000000003187","article-title":"Late onset invasive pulmonary aspergillosis in lung transplant recipients in the setting of a targeted prophylaxis\/preemptive antifungal therapy strategy.","volume":"104","author":"Herrera","year":"2020","journal-title":"Transplantation"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.2174\/13816128113199990332","article-title":"Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis.","volume":"19","author":"Bellmann","year":"2013","journal-title":"Curr Pharm Des"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/j.1600-6143.2009.02734.x","article-title":"Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness.","volume":"9","author":"Cadena","year":"2009","journal-title":"Am J Transplant"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ajt.13431","article-title":"Voriconazole exposure and risk of cutaneous squamous cell carcinoma, Aspergillus colonization, invasive aspergillosis and death in lung transplant recipients.","volume":"16","author":"Mansh","year":"2016","journal-title":"Am J Transplant"},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3109\/00365548.2012.691207","article-title":"Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients.","volume":"44","author":"Tofte","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.healun.2005.05.003","article-title":"Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction.","volume":"24","author":"Shitrit","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R31-20250607","first-page":"399","article-title":"Fungal infection in heart-lung transplant recipients receiving single-agent prophylaxis with itraconazole.","volume":"9","author":"Hayes","year":"2011","journal-title":"Exp Clin Transplant"},{"key":"R32-20250607","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tid.12497","article-title":"Posaconazole in lung transplant recipients: use, tolerability, and efficacy.","volume":"18","author":"Robinson","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R33-20250607","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/myc.12724","article-title":"Posaconazole liquid vs tablet formulation in lung transplant recipients.","volume":"61","author":"Stelzer","year":"2018","journal-title":"Mycoses"},{"key":"R34-20250607","doi-asserted-by":"crossref","first-page":"e13067","DOI":"10.1111\/tid.13067","article-title":"Why do lung transplant patients discontinue triazole prophylaxis?","volume":"21","author":"Pennington","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"R35-20250607","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/tri.12802","article-title":"Nebulized liposomal amphotericin prophylaxis in lung transplantation: shall we take it or leave it?","volume":"29","author":"Vianello","year":"2016","journal-title":"Transpl Int"},{"key":"R36-20250607","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R37-20250607","doi-asserted-by":"crossref","first-page":"e01643-18","DOI":"10.1128\/AAC.01643-18","article-title":"Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients.","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R38-20250607","doi-asserted-by":"crossref","first-page":"e12878","DOI":"10.1111\/tid.12878","article-title":"Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation.","volume":"20","author":"Kabulski","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"R39-20250607","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R40-20250607","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1093\/jac\/dkaa274","article-title":"Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube.","volume":"75","author":"McCreary","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R41-20250607","doi-asserted-by":"crossref","first-page":"e2019061","DOI":"10.4084\/mjhid.2019.061","article-title":"Rhino-orbital-cerebral mucormycosis after allogeneic hematopoietic stem cell transplantation and isavuconazole therapeutic drug monitoring during intestinal graft versus host disease.","volume":"11","author":"Andreani","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R42-20250607","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.healun.2009.11.603","article-title":"Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation.","volume":"29","author":"Monforte","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"R43-20250607","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bcp.14166","article-title":"A phase 1\/1b study of PUR1900, an inhaled formulation of itraconazole, in healthy volunteers and asthmatics to study safety, tolerability and pharmacokinetics.","volume":"86","author":"Hava","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"R44-20250607","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.01657-08","article-title":"Inhaled voriconazole for prevention of invasive pulmonary aspergillosis.","volume":"53","author":"Tolman","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R45-20250607","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1097\/TP.0000000000002697","article-title":"Aerosolization of second-generation triazoles: in vitro evaluation and application in therapy of invasive airway aspergillosis.","volume":"103","author":"Thanukrishnan","year":"2019","journal-title":"Transplantation"},{"key":"R46-20250607","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bcpt.12820","article-title":"Voriconazole concentrations in plasma and epithelial lining fluid after inhalation and oral treatment.","volume":"121","author":"Andersen","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R47-20250607","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ajt.14580","article-title":"Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.","volume":"18","author":"Sol\u00e9","year":"2018","journal-title":"Am J Transplant"},{"key":"R48-20250607","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4149\/neo_2013_042","article-title":"Prospective trial finds nystatin mouthwash effective prophylaxis for pulmonary invasive fungal infections that originate in the throat of patients with hematologic malignancies.","volume":"60","author":"Hu","year":"2013","journal-title":"Neoplasma"},{"key":"R49-20250607","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3201\/eid2606.191570","article-title":"Cannabis use and fungal infections in a commercially insured population, United States, 2016.","volume":"26","author":"Benedict","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"R50-20250607","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4067\/s0716-10182018000400351","article-title":"Evaluation of the prescription, consumption and costs of antifungal drugs in a pediatric hospital in Chile.","volume":"35","author":"Barraza","year":"2018","journal-title":"Rev Chilena Infectol"},{"key":"R51-20250607","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10198-017-0907-5","article-title":"Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","volume":"19","author":"Grau","year":"2018","journal-title":"Eur J Health Econ"},{"key":"R52-20250607","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/myc.12552","article-title":"Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.","volume":"60","author":"Solano","year":"2017","journal-title":"Mycoses"},{"key":"R53-20250607","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/lt.24365","article-title":"Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients.","volume":"22","author":"Balogh","year":"2016","journal-title":"Liver Transpl"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T16:14:05Z","timestamp":1749312845000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003717","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,22]]}}}